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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of evidence. 
Preparedness and Response 
Impact assessment of non-pharmaceutical interventions against coronavirus diseases 
2019 and influenza in Hong Kong: an observational study 
Cowling, BJ, Ali, ST, Ng, TWY et al. | The Lancet Public Health | 17 April 2020 | Article 
https://doi.org/10.1016/S2468-2667(20)30090-6 
This study suggests that non-pharmaceutical interventions (border restrictions, quarantine and 
isolation, social distancing and behaviour changes) quickly implemented to control the spread of 
COVID-19 in Hong Kong have been effective with the estimated effective reproduction number 
remaining at approximately 1 for the past 8 weeks and that these measures were able to avoid the 
need for complete lockdowns. These interventions also reduced influenza transmission in early 
February 2020. This study was not able to identify which measure was potentially the most effective 
in suppressing COVID-19 transmission, but it is likely that each played a part. The associated 
estimated 44% reduction in influenza transmission in the general community in February 2020, 
was much greater than reduction in transmission with previous school closures alone during the 
2009 pandemic and transmission of influenza B in 2017-18 suggesting that social distancing 
measures and avoidance behaviours have had a substantial effect on influenza transmission in 
addition to the effect of school closures. The experience from Hong Kong suggests that COVID-
19 transmission can be contained with a combination of testing and isolating cases, along with a 
level of social distancing to reduce community transmission from unidentified cases. If these 
measures and population responses are sustained they could help to avoid fatigue among the 
general population. 
Africa in the path of COVID-19 
El-Sadr, WM & Justman, J | NEJM | 17 April | Perspective 
https://www.nejm.org/doi/full/10.1056/NEJMp2008193 
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This Perspective calls for countries around the world to assist Africa in staying ahead of the curve, 
even as they confront their own epidemics. These may include donations of test kits, PPE, 
ventilators ad other life-support equipment, or at least ensuring that African countries are not priced 
out of the market for these commodities. Support for real-time COVID-19 surveillance systems and 
for surveys to determine the scale of the epidemic to inform decisions on how to respond. Support 
for information campaigns to promote and sustain safe behaviours and counter stigma that can 
arise. Social and economic support for the vulnerable and poor including those that work in the 
informal economy. Resources to respond to the COVID-19 pandemic must be additional and ot 
diverted away from ongoing health threats including TB, HIV and malaria. 
How to obtain a nasopharyngeal swab specimen 
Marty et al | NEJM | 17 April 2020 | Video 
https://www.nejm.org/doi/full/10.1056/NEJMvcm2010260 
This video demonstrates the collection of specimens from the surface of the respiratory mucosa 
with naopharyngeal swabs for the diagnosis of COVID-19 in adults and in children – important as 
inadequate swab technique could lead to false negative results. Approved PPE and the appropriate 
technique is important to minimise the possibility of spreading the virus. 
Demographic science aids in understanding the spread and fatality rates of COVID-19 
Dowd et al. | PNAS | 16 April 2020 | Brief report 
https://doi.org/10.1073/pnas.2004911117 
Demographically informed projections will better predict the COVID-19 burden and inform 
governments. The overall burden of serious cases and mortality reflects linkages between the age 
distribution of early cases, age structure of the population and intergenerational interactions. This 
study examined the role of age structure in deaths so far in Italy and South Korea and illustrate 
how the pandemic could develop in populations with similar sizes but different age structures e.g. 
Brazil vs Nigeria. Currently COVID-19 mortality is higher in countries with older versus younger 
populations. COVID-19 transmission chains that begin in younger populations may go undetected 
longer. Once community transmission is established, countries with high intergenerational contacts 
may see faster transmissions to high-fatality age groups, as seen in Italy and Spain. Reporting of 
case and fatality data disaggregated by age and sex will help improve real-time targeted 
forecasting of hospitalisation and critical care needs. 
Estimating the maximum capacity of COVID-19 cases manageable per day given a health 
care system’s constrained resources 
Giannakeas et al. | Annals of Internal Medicine | 16 April 2020 | Letter & Tool 
https://doi.org/10.7326/M20-1169 
This letter describes the development of an open access online tool – the COVID-19 Acute and 
Intensive Care Resource Tool (CAIC-RT) - that can be tailored for use in any region of the world 
and applied to either a large health care system or to an individual hospital to estimate the 
maximum number of COVID-19 cases that could be managed per day within the catchment area 
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serviced by a health facility or system, on the basis of age-based case distribution and severity 
and acute and critical care resource availability. Assumptions of this tool include that patients with 
COVID-19 are hospitalised instantaneously and that all beds and ventilators can be adequately 
staffed; and the application of Canadian, Chinese, Italian and US data may not be generalisations 
to all health care systems. Default values will be updated as new data emerge. 
Predictive mathematical models of the COVID-19 pandemic: underlying principles and 
value of projections 
Jewell et al | JAMA | 16 April 2020 | Viewpoint 
https://doi.org/10.1001/jama.2020.6585 
A caution that the “primary and most effective use of epidemiological models is to estimate the 
relative effect of various interventions in reducing disease burden rather than to produce precise 
quantitative predictions about extent or duration of disease burdens”. Estimates from modelling 
studies are only as good as the validity of the epidemiological or statistical model used; the extent 
and accuracy of the assumptions made and the quality of data (limited early in an epidemic and 
by reporting delays and poor documentation) used to calibrate the model. Models need to be 
dynamic to respond to unanticipated effects; key assumptions should be clearly reported; ranges 
of estimates should be reported so that the variability and uncertainty of predictions is clear; models 
should incorporate measures of accuracy as additional or better data becomes available; and 
models should reflect local data to represent context. 
Intersectional approach to COVID-19 
The risks posed by COVID-19 are gendered. Our response should be as well 
Bourgault S | Center for Global Development | 17 April 2020 | Blog 
https://www.cgdev.org/blog/risks-posed-covid-19-are-gendered-our-response-should-be-well 
In a recent CGD event, experts discussed the impact of the pandemic on violence against women, 
care burdens, social norms, economic prospects and more. This blog summaries key messages 
from this event. 
Disability and COVID-19: What did we learn from the Twitter Chat 
ARISE Consortium | 20 April 2020 | Blog on Twitter Chat 
http://www.ariseconsortium.org/disability-and-covid-19-what-did-we-learn-from-the-twitter-chat/ 
All blogs summarising key learnings from the ARISE Twitter chat on 6 April are now available. The 
fourth blog covers structural violence, ableism and COVID-19. 
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Research and Development 
Bacille Calmette-Guérin (BCG) vaccination and COVID-19 
WHO | 12 April 2020 | Scientific Brief 
https://www.who.int/news-room/commentaries/detail/bacille-calmette-guérin-(bcg)-vaccination-
and-covid-19 
WHO does not recommend BCG vaccination for the prevention of COVID-19 in the absence of 
evidence. WHO will evaluate the evidence when available. Two clinical trials are currently 
underway. 
Economic impact 
The economic impact of COVID-19 around the world: a round-up of the most recent 
analysis 
Acosta, AM & Evans, D | Center for Global Development | 17 April 2020 | Blog 
https://www.cgdev.org/blog/economic-impact-covid-19-around-world-round-most-recent-
analysis#evans-economic-africa 
A selection of recent coverage on the observed and expected economic impacts across Africa, 
Asia and Latin America, divided into growth and income, sectors and sub-populations, policy 
responses, and commentary. Note that the recurring theme in the analysis across Africa and Asia 
is potential disruptions to the food chain. 
Online learning and events 
CGD conversations on COVID-19 and development: Mark Lowcock 
Tuesday 28 April 2020 1200 ET 
https://www.cgdev.org/event/cgd-conversations-covid-19-and-development-mark-lowcock 
Under-Secretary General for Humanitarian Affairs and Emergency Relief Coordinator, Mark 
Lowcock, joins CDG President Masood Ahmed to discuss the impacts of the COVID-19 pandemic 
in fragile states and refugee communities. 
Emerging respiratory viruses, including COVID-19: methods for detection, prevention, 
response and control 
WHO | Free | 3 hours duration  
https://openwho.org/courses/introduction-to-ncov 
A general introduction to enable you to describe the fundamental principles of emerging 
respiratory viruses, including novel coronaviruses, and how to effectively respond to an outbreak. 
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Intended for public health professionals, incident managers and personnel working for the UN, 
international organisations and NGOs. 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 25 May 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
Unfacilitated access to this course remains. An updated version of this course will though be run 
from 25 May 2020. On this course you will learn what is known about the outbreak of COVID-19 
(week 1); what the practical implications for responding to COVID-19 are (week 2); and what we 
need to find out about COVID-19 (week 3). 
COVID-19 Diagnostics and Testing 
FIND, LSHTM & ASLM | FutureLearn course | Starts 20 April 2020 | 3 weeks | 3 hours weekly 
study | Free 
https://www.futurelearn.com/courses/covid-19-diagnostics-and-testing 
This course is designed for professionals involved in the testing and diagnosis of COVID-19, with 
a focus on low- and middle-income settings. You will learn the latest recommendations on COVID-
19 testing, get upt0date information on the performance of tests and how best to deploy them. 
COVID-19 Critical Care: Understanding and Application 
University of Edinburgh & Royal College of Physicians of Edinburgh  | FutureLearn course | 
Starts 6 April 2020 | 5 weeks | 1 hour weekly study | Free 
https://www.futurelearn.com/courses/covid-19-critical-care-education-resource 
Designed for frontline clinical staff to learn the principles and practice of critical care to treat and 
care for critically ill patients during the COVID-19 pandemic. You will learn (1) how to apply the 
current and evolving principles of PPE in the care of COVID-19; (2) apply evidence-based 
principles of advanced organ support and monitoring to the COVID-19 critically ill patients; (3) 
apply evidence-based daily practices to care of the critically ill patient; and (4) develop a range of 
specialised self-caring practices. 
Note that this resource has been created in response to the COVID-19 emergency and does not 
correspond to the classic structure of a FutureLearn course. You do not have to follow the week 
by week approach and can select the materials most relevant to your work. 
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Tracking Dashboards 
Global WHO sitreps 
 Johns Hopkins University  
 WEF 
 Vaccine Centre LSHTM 
 Our World in Data 
 Global 5050 
 Humanitarian Data Exchange 
 Information is Beautiful 
 The Commons Project 
Regional  WHO Africa  
 African Arguments 
 European CDC 
Country Ghana 
 Indonesia 







Regional Africa CDC 
Country Nigeria CDC 
 UK Government 
 UK ONS 
 NICE UK 
 US CDC 
Resource Hubs 
Multilaterals WHO 
 WHO risk communication 
 WHO Q&A 
 
WHO Global research 
COVID-19 Solidarity Response Fund 
 UN 







 UN WFP 
 World Bank 











 Cochrane reviews 
Global Health Institutes LSTM 
 LSHTM 
 Johns Hopkins University 
 ICL MRC Centre for Global Infectious Disease Analysis  
 ODI 
 Norwegian Institute of Public Health 
Ethics Rings HSG Resyst Reach Wellcome  
Clinical trials US NIH registered clinical trials  
Funding bodies UKRI 
 Wellcome 
Demographics WorldPop 
Global Impact Surveys Premise COVID-19 Global Impact Study 
 GeoPoll: SSA 
TB Stop TB Partnership 
Disability IDA 
 Disability and inclusion 
 Coregroup IDDC  
SDGs Global Partnership for Sustainable Development Data  
Humanitarian Reliefweb 
 Humanitarian OpenStreetMap Team  
 SSHAP 
Narratives David Nabarro, WHO DG Special Envoy on COVID-19 
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About this report 
This daily COVID-19 health evidence summary is based on 3 hours of desk-based research. K4D services are 
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Response Institute (HCRI). 
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Development (DFID) and its partners in support of pro-poor programmes. It is licensed for non-
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consequences arising from the use of information contained in this health evidence summary. 
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